Lumos Pharma, INC.: insider trades · United States · SEC (Form 4)

About Lumos Pharma, INC.

Lumos Pharma, Inc. is a United States-based biopharmaceutical company that was historically listed on the Nasdaq Global Market under the ticker LUMO and was headquartered in Austin, Texas, with additional administrative operations in Ames, Iowa. For French-, Belgian-, and Swiss-based investors, the company represents a highly specialized small-cap biotechnology story rather than a diversified pharma platform. Its corporate history traces back to NewLink Genetics Corporation, the original Delaware-incorporated entity, which later combined with the private Lumos Pharma business in March 2020 and adopted the Lumos Pharma name. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1126234/000112623424000097/nlnk-20240930.htm?utm_source=openai)) The company’s business model has been centered on rare-disease drug development, with its lead and essentially sole product candidate being LUM-201, also known as ibutamoren. LUM-201 is an oral growth hormone secretagogue in clinical development for idiopathic pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. That single-asset concentration gives the company a classic clinical-stage biotech risk profile: substantial upside if the program succeeds, but heavy dependence on trial execution, FDA interactions, and access to capital. Lumos has positioned the oral route of administration as an important differentiator versus more burdensome treatment options, which is relevant in pediatric and rare-disease settings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1126234/000112623424000097/nlnk-20240930.htm?utm_source=openai)) From a competitive standpoint, Lumos Pharma operated in a niche segment where scientific specialization, regulatory progress, and clinical evidence matter more than broad commercial scale. The company targeted conditions with high unmet medical need, which can create meaningful barriers to entry and support premium therapeutic value if the product profile is validated. At the same time, this also means the company’s competitive standing depended largely on the strength of its clinical data package and the progression of its lead program rather than on a wide product portfolio or established sales infrastructure. ([lumos-pharma.com](https://lumos-pharma.com/our-company/?utm_source=openai)) Recent corporate developments were especially important. In May 2024, Lumos Pharma announced a positive end-of-Phase 2 meeting with the FDA, a constructive regulatory milestone for the LUM-201 program. In October 2024, the company announced a definitive merger agreement with Double Point Ventures under which DPV would acquire Lumos Pharma for $4.25 per share in cash plus one contingent value right per share, subject to milestone outcomes. The company later stated that Lumos Pharma’s NASDAQ-listed stock ceased trading on December 12, 2024 following the acquisition. For investors analyzing SEC Form 4 insider transactions, this matters because the company should now be viewed through the lens of a former public biotech that has been taken private, rather than an active standalone listed issuer. ([investors.lumos-pharma.com](https://investors.lumos-pharma.com/news-releases/news-release-details/lumos-pharma-announces-positive-end-phase-2-meeting-fda-and?utm_source=openai))